Caribou Biosciences, Inc. (CRBU) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Caribou Biosciences, Inc. (CRBU:NASDAQ), powered by AI.

Current Price
$1.59
P/E Ratio
-1.0
Market Cap
149M
Sector
Healthcare
What is the Caribou Biosciences, Inc. stock price forecast?

Caribou Biosciences, Inc. is currently trading at $1.59. View real-time AI analysis on Alpha Lenz.

What is Caribou Biosciences, Inc. insider trading activity?

View the latest insider trading data for Caribou Biosciences, Inc. on Alpha Lenz.

What is Caribou Biosciences, Inc.'s P/E ratio?

Caribou Biosciences, Inc.'s P/E ratio is -1.0.

Caribou Biosciences, Inc.

NASDAQ · CRBU
$1.59-0.06(-3.92%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Caribou Biosciences, Inc.'s future dividend policy...
Alpha Chat Insight

Caribou Biosciences, Inc. trades at a P/E of -1.0 (undervalued) with modest ROE of -79.0%.

Ask for details

Company Overview

Caribou Biosciences Inc. is at the forefront of biotechnology, specializing in genome-editing technologies. This company primarily focuses on developing novel therapeutic solutions by leveraging CRISPR-derived gene-editing platforms. With its innovative approach, Caribou aims to address critical challenges in disease treatment, particularly in areas such as oncology and immunology. The company's pioneering work in advancing genetic therapies highlights its pivotal role in the rapidly evolving biotech sector. Caribou Biosciences collaborates with academic institutions and industry leaders to translate complex genomic research into tangible medical therapies, fostering advancements in personalized medicine. The company's deep commitment to scientific excellence propels its influence in the gene-editing landscape, highlighting its importance in the nascent yet potent therapeutic area of genome manipulation. By steering the development of cutting-edge gene-editing applications, Caribou Biosciences is instrumental in shaping the future of bioengineering and therapeutic interventions.

CEODr. Rachel E. Haurwitz Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees147

Company Statistics

FY 2025

Profile

$148.96MMarket Cap
$11.16MRevenue
0.00Shares Out
147Employees

Margins

N/AGross
-996.87%EBITDA
-1220.49%Operating
-1332.33%Pre-Tax
-1327.40%Net

Valuation

-1.01P/E
1.22P/B
13.35EV/Sales
-1.47EV/EBITDA
-1.33P/FCF

Growth (CAGR)

-6.95%Rev 3Yr
-2.03%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-60.62%ROA
-78.97%ROE
-55.74%ROIC

Financial Health

$12.36MCash & Cash Equivalents
$40.83MNet Debt
43.54%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Caribou Biosciences, Inc. (ticker: CRBU) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 147 employees. Market cap is $149M.

The current price is $1.595 with a P/E ratio of -1.01x and P/B of 1.22x.

ROE is -78.97% and operating margin is -1220.49%. Annual revenue is $11M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Caribou Biosciences, Inc. (CRBU) Stock Forecast 2026 $1.59 — Price, Financials & Analyst Targets | Alpha Lenz